Pilot study: Imatinib for the treatment of plexiform neurofibromas in NF1 patients. - Ima-NF1-2012

ISTITUTO NEUROLOGICO CARLO BESTA0 个研究点开始时间: 2012年3月8日最近更新: 2014年2月3日

适应症

试验速览

暂无简介。

•clinical diagnosis of NF1 according US National Institute of Health Consensus criteria, age at entry >3 < 65, and the presence of a measurable disabling or disfiguring plexiform neurofiroma that is not amenable to total surgical resection. Disabling PNF is defined as a tumor causing motor weakness by compression of the spinal cord or pain due to infiltration of spinal roots or limitation of limb mobility due to local mass effect. Disfiguring PNF is defined as an infiltranting tumor in the head and neck region with major cosmetic impairment, resulting in distress to the patient. Patients have to have a Lasky (children < 10 years) or Karnofsky (patients > 10 years) performance levels > 50. Radiographic progression is not a necessity for patient entry.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 3
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 3
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Patients undergoing radiation,chemotherapy, hormonal therapy, directed to the tumor or immunotherapy were excluded from partecipation. Other exclusion criteria are the presence of an active optic glioma or other tumor requiring radiation or chemotherapy.

发起方

ISTITUTO NEUROLOGICO CARLO BESTA